



# TARGETING METABOLIC DYSREGULATION IN NASH:

Exploring Novel Strategies to Mitigate Hepatic and Cardiovascular Disease

## REFERENCES

### Cardiovascular Disease Risk and Nonalcoholic Fatty Liver Disease

Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291-1300. doi:10.1056/NEJMoa1415516

Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2020;51:728-736. doi:10.1111/apt.15660

Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2021;6:903-913. doi:10.1016/S2468-1253(21)00308-3

Meyersohn NM, Mayrhofer T, Corey KE, et al. Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease. *Clin Gastroenterol Hepatol*. 2021;19:1480-1488.e14. doi:10.1016/j.cgh.2020.07.030

Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol*. 2019;17:2776-2784.e4. doi:10.1016/j.cgh.2019.04.061

Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. *Diabetes Metab*. 2021;47:101215. doi:10.1016/j.diabet.2020.101215

### Emerging Targeted Strategies to Mitigate Disease Progression in NAFLD/NASH

Calle RA, Amin NB, Carvajal-Gonzalez S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. *Nat Med*. 2021;27:1836-1848. doi:10.1038/s41591-021-01489-1

Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. *Ann Intern Med*. 2016;165:305-315. doi:10.7326/M15-1774

# REFERENCES Continued

## Emerging Targeted Strategies to Mitigate Disease Progression in NAFLD/NASH

Ghazanfar H, Kandhi SD, Nawaz I, et al. Role of glucagon-like peptide-1 receptor agonists in the management of non-alcoholic steatohepatitis: a clinical review article. *Cureus*. 2021;13:e15141. doi:10.7759/cureus.15141

Gepner Y, Shelef I, Schwarzfuchs D, et al. Effect of distinct lifestyle interventions on mobilization of fat storage pools: central magnetic resonance imaging randomized controlled trial. *Circulation*. 2018;137:1143-1157. doi:10.1161/CIRCULATIONAHA.117.030501

Harrison SA, Guy CD, Bashir M, et al. In a placebo-controlled 36-week phase 2 trial, treatment with Mgl-3196 compared to placebo results in significant reductions in hepatic fat (MRI-PDFF), liver enzymes, fibrosis biomarkers, atherogenic lipids, and improvement in NASH on serial liver biopsy. *Hepatology*. 2018;68(1 suppl):9A-10A. doi:10.1002/hep.30256

Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2019;394:2012-2024. doi:10.1016/S0140-6736(19)32517-6

Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. *Gastroenterology*. 2021;160:219-231.e1. doi:10.1053/j.gastro.2020.08.004

Holmer M, Lindqvist C, Petersson S, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. *JHEP Rep*. 2021;3:100256. doi:10.1016/j.jhepr.2021.100256

Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. *Gastroenterology*. 2020;159:1290-1301.e5. doi:10.1053/j.gastro.2020.06.006

Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N Engl J Med*. 2021;384:1113-1124. doi:10.1056/NEJMoa2028395

Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. *Endocrinol Diabetes Metab*. 2019;3:e00105. doi:10.1002/edm2.105

Patton H, Heimbach J, McCullough A. AGA clinical practice update on bariatric surgery in cirrhosis: Expert review. *Clin Gastroenterol Hepatol*. 2021;19:436-445. doi:10.1016/j.cgh.2020.10.034

Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol*. 2017;67:829-846. doi:10.1016/j.jhep.2017.05.016

Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology*. 2018;68:361-371. doi:10.1002/hep.29724

Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet*. 2019;394:2184-2196. doi:10.1016/S0140-6736(19)33041-7